# Sequence Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sequence-bio

- Industry: Pharmaceuticals
- Headquarters: St. John's, Canada
- Website: www.sequencebio.co
- Total disclosed funding: $4M
- Latest round: Seed (Aug 3, 2016)
- Investors on record: 4

## About

Sequence Bio is a biotechnology firm focused on systems biology and data-driven computation to facilitate the discovery of targeted therapies for diverse diseases.Founded in 2013, Sequence Bio operates from St. John's, Canada, specializing in enhancing the discovery of therapies through data integration. The company has undergone two investment deals, with its most recent funding round being a Seed round of CAD 3.9 million from Data Collective and other investors, completed on August 3, 2016. Lynn Healey and Sam Rasty are the current CEOs of the company.Sequence Bio specializes in systems biology and data-driven computation to enhance the discovery of targeted therapies for both common and rare diseases. The company integrates a comprehensive array of resources, including founder population multi-omics, real-world patient data, and well-characterized phenotypes, to create customized discovery cohorts tailored to the needs of pharmaceutical and biotechnology partners. This collaborative approach facilitates the identification of disease signals that can lead to the development of more effective medicines. The primary clients of Sequence Bio include leading pharmaceutical companies and biotech firms that seek to leverage this unique platform to expedite their research and development timelines. The company's offerings are particularly focused in North America and Europe, where they engage with various health and research institutions to advance their initiatives.Sequence Bio generates revenue through strategic partnerships and collaborations with pharmaceutical and biotech companies, which typically involve bespoke discovery cohort projects. These partnerships facilitate a streamlined process for conducting research and development, wherein clients benefit from tailored solutions that address specific therapeutic areas. The revenue structure is based on contractual agreements that outline project scopes, deliverables, and payment terms, reflecting the complexity and customization of the services provided. While specific pricing plans are not disclosed, the transactions encompass various models, including fixed fees for project-based services or long-term engagements that align with clients’ R&D goals. The company’s flagship offerings support its mission to improve health outcomes, contributing to the overall financial sustainability of its operations.In August 2016, Sequence Bio raised CAD 3.9 million in Seed financing led by Data Collective, which will support the company in advancing its product offerings and expanding its market reach. The firm is focused on launching new data-driven solutions designed for targeted therapies, with plans to enter additional markets in North America and Europe by 2025. This funding will enable the development of new partnerships and enhance their technological capabilities.

## Funding rounds

- Seed, Aug 3, 2016, $3M — DCVC, Killick Capital, Klister Credit, Pelorus Venture Capital
- Seed, Oct 19, 2015, $1M — Killick Capital, Klister Credit, Pelorus Venture Capital

## Investors

- Killick Capital (https://capitalatlas.ai/funds/killick-capital) — Seed
- Klister Credit — Seed
- Pelorus Venture Capital (https://capitalatlas.ai/funds/pelorus-venture-capital) — Seed
- DCVC (https://capitalatlas.ai/funds/dcvc) — Seed